Characteristics of the study participants with systemic lupus erythematosus.
| Patient | Age, yrs/Sex | Disease Duration, mo | CS Dose, mg | Treatments Prior to RTX | Organ Involvement | Anti-dsDNA antibody, IU/ml | ENA | C3/C4/CH50 | ANA | CS Dose at 2 yrs | SLEDAI Day 0 to 2 yrs | BILAG Day 0 to 2 yrs | Clinical Response at 2 yrs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 F | 144 | 22.5 | IVCY, CsA | nephritis (II) | 123.2 | Ro, Sm, RNP | 52/< 5/26 | 2560 | 5 | 10→0 | 15→0 | MCR |
| 2 | 21 F | 84 | 12.5 | IVCY, MTX | CNS | 1.4 | Ro, RNP | 105/19/49 | 320 | 6 | 3→0 | 15→1 | MCR |
| 3 | 20 F | 10 | 25 | IVCY | CNS | < 1.0 | — | 119/24/53 | < 40 | 10 | 10→0 | 13→0 | MCR |
| 4 | 41 F | 324 | 60 | IVCY, PE | CNS, TTP nephritis (IV) | 500.6 | Sm, RNP | 28/< 5/13 | 10240 | 9.5 | 20→0 | 28→0 | MCR |
| 5 | 32 F | 252 | 60 | IVCY | CNS nephritis (IV) | 8.4 | — | 56/12/27 | < 40 | 2 | 28→2 | 25→0 | MCR |
| 6 | 29 F | 6 | 30 | IVCY | lymphadenopathy | 5.4 | — | 114/18/31 | 320 | 7.5 | 9→17* | 12→21* | NCR* |
| 7 | 17 M | 3 | 30 | MMF | nephritis (IV) | 6.3 | — | 103/26/55 | < 40 | 5 | 18→2 | 13→0 | MCR |
| 8 | 32 F | 108 | 50 | IVCY, CsA, AZA, PE | nephritis (IV) | 52.3 | Ro, Sm, RNP | 90/15/39 | 640 | 7 | 16→0 | 17→0 | MCR |
| 9 | 16 F | 30 | 20 | ICVY, MZ, CsA | nephritis (IV) CNS | 610.7 | Ro | 54/8/25 | 320 | 12.5 | 13→10* | 23→13* | NCR* |
| 10 | 27 F | 6 | 40 | IVCY, PE IA | nephritis (IV) | 242.1 | — | 35/< 5/9 | 1280 | 2.5 | 35→4 | 37→3 | MCR |
↵* At relapse. RTX: rituximab; CNS: central nervous system; ANA: antinuclear antibody; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; BILAG: British Isles Lupus Assessment Group Activity Index; CS: prednisolone (or equivalent); CY: cyclophosphamide; IVCY: intravenous cyclophosphamide pulse therapy; CsA: cyclosporin; MZ: mizoribine; PE: plasma exchange; IA: immune adsorption; AZA: azathioprine; MMF: mycophenolate mofetil; TTP: thrombotic thrombocytopenic purpura; ENA: extractable nuclear antigen; AIHA: autoimmune hemolytic anemia; MCR: major clinical response; NCR: no clinical response.